Biotech · Private company
Rakuten Medical, Inc.
Track this companyFree. Adds Rakuten Medical, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials74 recruiting or active
Pipeline programs14From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline14
- 5-fluorouracilPhase 3 · Recurrent Head and Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- ASP-1929 PhotoimmunotherapyPhase 3 · Recurrent Head and Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- ASP-1929 PhotoimmunotherapyPhase 3 · Head and Neck CancerClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 3 · Recurrent Head and Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- CisplatinPhase 3 · Recurrent Head and Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- PaclitaxelPhase 3 · Recurrent Head and Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 3 · Recurrent Head and Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Physician's Choice SOCPhase 3 · Head and Neck CancerClinicalTrials.gov · fetched Nov 12, 2026
- 200 mg PembrolizumabPhase 2 · Recurrent Head and Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- 350 mg CemiplimabPhase 2 · Recurrent Head and Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- ASP-1929 PITPhase 2 · Recurrent Head and Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- PIT: 100 J/cm^2 for superficial lesions or 200 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2Phase 2 · Recurrent Head and Neck CancerClinicalTrials.gov · fetched Nov 12, 2026
- PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 160 mg/m^2Phase 2 · Recurrent Head and Neck CancerClinicalTrials.gov · fetched Nov 12, 2026
- PIT: 75 J/cm^2 for superficial lesions or 150 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2Phase 2 · Recurrent Head and Neck CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic CancerPHASE1_PHASE2 · NOT_YET_RECRUITING · started Sep 1, 2026ClinicalTrials.gov NCT07698613 · fetched Nov 12, 2026
- Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung CancerPHASE2 · WITHDRAWN · started Aug 15, 2026ClinicalTrials.gov NCT06943664 · fetched Nov 12, 2026
- A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant MetastasesPHASE3 · RECRUITING · started Dec 24, 2024ClinicalTrials.gov NCT06699212 · fetched Nov 12, 2026
- ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck CancerPHASE2 · UNKNOWN · started Jan 21, 2022ClinicalTrials.gov NCT05182866 · fetched Nov 12, 2026
- An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid TumorsPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Dec 21, 2020ClinicalTrials.gov NCT04305795 · fetched Nov 12, 2026
- ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of TherapyPHASE3 · ACTIVE_NOT_RECRUITING · started May 9, 2019ClinicalTrials.gov NCT03769506 · fetched Nov 12, 2026
- Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck CancerPHASE1_PHASE2 · COMPLETED · started Jun 1, 2015ClinicalTrials.gov NCT02422979 · fetched Nov 12, 2026